Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.
about
Inhibition of Nodal suppresses angiogenesis and growth of human gliomasVanadate-induced expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen speciesPathways for aberrant angiogenesis in pancreatic cancerAT1 receptor is present in glioma cells; its blockage reduces the growth of rat gliomaDistinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cellsThe role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypesXL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma.HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now?Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration.In vivo characterization of several rodent glioma models by 1H MRSGlioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography.Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastomaA mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesisThe significance of immunohistochemistry in the diagnosis and therapy of neoplasms.Pathological significance of vascular endothelial growth factor A isoform expression in human cancer.Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapyAnti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionPhase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyAngiogenic factors in the central nervous system.Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigationHost microvasculature influence on tumor vascular morphology and endothelial gene expressionDistinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis.Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2Emerging targeted treatments for malignant glioma.Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vesselsUpregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis.Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.
P2860
Q24309876-58CCE083-5D8A-48E6-93A7-4B224ED821ECQ24720804-C42E08FE-34EB-4FFE-B1B1-103EDD9FA837Q24800215-E3715E5A-6DAF-4140-9D7E-C33B22AE2765Q28365043-DA3538C6-A15E-4F41-82BB-A888D4B68753Q28582266-949D1ACE-9C3A-4560-A64B-02466F003947Q30307781-A0014509-E53F-45B6-9B25-0541E433974AQ30415151-8233053A-312A-4CD2-B5E9-368273DA0C29Q30428632-4764B558-6EBF-4BC0-AA3B-009451ECC783Q30724216-82D01DAD-474C-4D75-BDE2-3FEEEFD5415DQ30828692-9EBEE717-C90F-4F4D-AC6F-0A04A2816B4BQ30854194-BC6C43F6-2E15-4880-AC4E-5CAB0DBD5F58Q31104595-0FCFDC60-2C88-4F57-BF1B-89BA5388A07AQ33630409-82FD4AE0-D45F-4968-AB60-296C8C18B653Q33808359-20D3C0F9-4083-42FC-85BE-1FA2DEAF1239Q33943213-838D467D-D078-468F-BDB8-88A6EA6CD387Q34033507-1B11E398-6402-4C7B-A7A2-B4D1EEEE9F8EQ34041524-C97F59A4-1C0C-40D1-9943-7EC9B7A1D8A5Q34136521-A02C55CF-00ED-4E2D-99FB-FF7FF6EECD9BQ34203930-A2040ABF-AFB2-44FE-AD2D-2A69A745D32AQ34424899-DF0ADC47-5D05-42B1-8708-2A43A2A81558Q34568957-2765E2DD-C4DD-4ADB-9BD5-5E4C5B5FF273Q34602545-9D85D869-22B6-4FFD-BD5A-5A1AF6CF1D0EQ34722935-F1090F3E-2E18-43F3-9103-2D970EE23E0AQ34743875-856D9921-90DF-412D-AE0F-171381D3115AQ34997337-D57A46A7-1F39-4FF3-85ED-89DB5CA7314BQ35114460-256ADF49-7A54-4F71-9822-5AF125422A56Q35207666-972FA2CB-E5E1-437F-B5A4-11FAB0ABB77CQ35695799-70AF9B12-58AA-4666-A7CF-080A9F54F584Q35753521-9DC15A72-D3CD-4974-9569-3C89B3BAEF44Q35791487-B9FA14C0-405C-42C2-8E50-B3CB428C6F57Q35793483-77BA802B-8550-4BE1-9580-216F6E5B5927Q36006105-60F6C9FB-C04D-4935-8CA2-794FF2FFFC17Q36006469-3E2996D9-B646-4EE0-8B14-37C31DF898E9Q36181201-93B14835-1D58-420A-8DEE-AD2227F73A39Q36220799-757E2C03-CE21-4A1C-9AC0-D2338AC559C6Q36223383-1B17520C-BAE7-43D6-A2A0-86891251043CQ36302855-F5433E91-2EA3-4C3C-A85D-15C3DBCEF518Q36357421-CBE72FCC-C258-495B-87BF-9162DDDEF2CAQ36380713-6436C9F7-14F9-4EFD-917E-423633899002Q36397313-C17CE606-1927-4560-B384-3F3D48777CC0
P2860
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suppression of glioblastoma an ...... lar endothelial growth factor.
@en
Suppression of glioblastoma an ...... lar endothelial growth factor.
@nl
type
label
Suppression of glioblastoma an ...... lar endothelial growth factor.
@en
Suppression of glioblastoma an ...... lar endothelial growth factor.
@nl
prefLabel
Suppression of glioblastoma an ...... lar endothelial growth factor.
@en
Suppression of glioblastoma an ...... lar endothelial growth factor.
@nl
P2093
P2860
P356
P1476
Suppression of glioblastoma an ...... lar endothelial growth factor.
@en
P2093
W K Cavenee
P2860
P304
P356
10.1073/PNAS.93.16.8502
P407
P577
1996-08-01T00:00:00Z